Meet Patricia

70-year-old retired lawyer and volunteer who cherishes her self-reliance and visiting with her grandchildren.

With my kidney cancer, I couldn’t volunteer anymore but that’s fine with me. If I can keep caring for myself and visiting with my grandkids, then that’s all I need.”

MEDICAL HISTORY: Found blood in her urine and a lump in her abdomen

INITIAL DIAGNOSIS: Advanced renal cell carcinoma (RCC) with a clear cell histology and lytic bone metastases; scheduled for nephrectomy


  • RCC is metastatic and Patricia is treatment naïve
  • ECOG performance status: 2
  • MSKCC risk: poor
  • Karnofsky performance status (KPS): 50%

In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:

12% of patients had a poor MSKCC risk

42% of patients had ≥3 involved organs
Patient age ranged from 18 to 88 years

When choosing first-line treatment, what therapy do you consider?

Hypothetical patient case study.

References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.